Epinastine is a second-generation antihistamine with mast cell stabilizing properties, primarily used in the treatment of allergic conjunctivitis. It selectively blocks histamine H₁ receptors and inhibits the release of inflammatory mediators from mast cells, providing both preventive and symptomatic relief.
Epinastine is available as an ophthalmic solution for topical administration.
Indications include:
∙ Seasonal allergic conjunctivitis
∙ Perennial allergic eye conditions
∙ Off-label: rhinitis (in some oral formulations, where approved)
Parent: Epinastine
Parent: Epinastine
Epinastine is synthesized via heterocyclic chemistry involving substituted imidazopyridines. Impurities may arise during synthesis, formulation, or degradation. For ophthalmic use, impurity limits are stringent under ICH Q3A/B and USP/EP guidelines due to direct contact with sensitive ocular tissues.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Epinastine is used to treat itching and inflammation of the eyes caused by allergic conjunctivitis, offering both antihistamine and mast cell-stabilizing effects.
It blocks H₁ histamine receptors and prevents histamine release from mast cells, reducing symptoms like itching, redness, and watering of the eyes.
Store at room temperature, protected from light and contamination. Once opened, the product should be used within 28 days unless otherwise stated.
Yes, it is generally well-tolerated for seasonal use, but long-term safety should be assessed by a healthcare provider.
